'Not bad,' 1st-time busker delighted to earn S$125.30 after 40 minutes
SINGAPORE: When a woman who tried her hand (or should we say, voice) at busking for the first time earlier this week, it turned out to be a pleasant surprise for her and her keyboardist, thanks to a supportive 'angel' and those who gathered round to watch them perform.
Rong Tin documented her experience on TikTok, where she showed that it was more nerve-wracking than probably most of us could ever imagine. @rongtinn
Will be busking again this wed (28/5, from ard 7:30-9:30pm) in front of The Cathay! Come find me if you are free ❤️ #sg #busking
♬ original sound – Ronggg
While she was 'super excited' about the experience, her first foray into busking did not start out smoothly at all, as the keyboard bag of her accompanist broke just as they left the car and headed outside 313@Somerset mall, where they were set to perform, which made her wonder if it was a 'sign' of things to come that evening.
Luckily, the bag was soon fixed by her 'awesome partner,' and they set up soon after.
However, she was beset by doubts, thinking, 'What if nobody stops to watch our performance at all? What if we don't get a single cent from today?'
The location hardly helped, as she realized while beginning to sing that her voice needed to compete with the other noises in the vicinity, leading her to quip, 'Now I know why nobody actually picks this location.'
Nevertheless, not one to give up, they continued singing, and things began to turn when she saw one woman filming them.
'She looks like an angel to me,' she said. And then, another woman dropped a S$50 bill into the keyboard case, which served as their donation box.
In her video, Ms Rong thanked the two women, giving them a special shoutout because after that, 'magically,' more people began dropping money into the case, and at one point, a small crowd had gathered around them.
They ended at 9:40 p.m. after their speaker ran out of battery, and counted their earnings in the car. Ms Rong and her partner ended up making S$125.30 for their maiden 40-minute performance and headed out to get 'a nice supper' afterward.
'I think that's not bad,' she said, adding that they also got a new speaker from the money they made that night.
Ms Rong also performed on Wednesday night in front of The Cathay.
Here's a sample of her lovely voice. @rongtinn
Want to turn your hobby into a source of income? Download WerkSG now 😀 Not only can u list ur services but also look for plenty of job opportunities! Most importantly, it's free for all to use @WerkSG #fyp #werksg #sg #sgjobs
♬ original sound – Ronggg – Ronggg
You can find out more about Ms Rong here. /TISG
Read also: This is why SG 'is one of the safest countries in the world' — Man asks busker to make announcement after car owner leaves window open
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Straits Times
an hour ago
- Straits Times
Cancer biotech firm Hummingbird Bioscience to target inflammatory diseases with precision drugs
Sign up now: Get ST's newsletters delivered to your inbox Hummingbird Bioscience recently received an award from the World Intellectual Property Organisation, the UN agency dedicated to innovation and creativity. SINGAPORE – Singapore-headquartered biotech firm Hummingbird Bioscience, known for developing antibodies for cancer, is turning its sights to drugs for immunology and inflammatory diseases, such as lupus and inflammatory bowel disease. It will be adapting antibody-drug conjugates which it developed for cancer treatment to target these diseases. It is now about 12 months to 18 months away from filing regulatory approvals in Asia, Europe and the US to start clinical trials for an undisclosed number of these drugs. These consist of antibodies that have the missile-like ability to seek out specific targets, along with a payload, which is a drug intended to treat a disease. Hummingbird recently received an award from the World Intellectual Property Organisation (Wipo), the United Nations agency dedicated to innovation and creativity. At the 2025 Wipo Global Awards held at the organisation's headquarters in Geneva on July 11, it was among 10 small and medium -sized enterprises worldwide that were celebrated for commercialising their intellectual property (IP). 'Hummingbird Bioscience exemplifies how innovative companies can thrive with a well-crafted IP strategy. The company has built a robust IP plan with a strong patents portfolio and a successful licensing-based business model,' said Mr Fu Zhikang, director of IP strategy solutions at Ipos International, a subsidiary of the Intellectual Property Office of Singapore. The biotech firm is looking to expand its pipeline of products. Its chief scientific officer and co-founder Jerome Boyd-Kirkup told The Straits Times: 'Our mission has been to build the next generation of potentially transformative therapies for patients with cancer and autoimmune diseases. 'A large part of that is to have a strong IP portfolio which can underpin that development and ensure that the innovations that are done here in Singapore can be translated globally.' The company's focus for the future will be on immunology and inflammation, said Dr Boyd-Kirkup. These diseases are a group of chronic conditions characterised by a dysregulated immune system leading to inflammation and tissue damage. It is generally believed that up to 10 per cent of the world's population is affected by these conditions, though estimates vary. The therapeutics for immunology and inflammatory diseases have seen keen interest from biopharma companies worldwide – the global market size for this area is projected to grow from US$103 billion (S$132.4 billion) in 2024 to US$257 billion by 2032. In the context of immunology and inflammatory diseases, the target for Hummingbird's antibody-drug conjugates may be immune cells that have become overactive or destructive, and a drug is selected to block the harmful response. Dr Boyd-Kirkup said that current treatments for immunology and inflammatory diseases are usually small molecule drugs such as corticosteroids and non-steroidal anti-inflammatory drugs. But the drawbacks of these drugs include concerns around side effects from long-term usage, and a short half-life, which means a drug needs to be taken more often as it does not stay long in the body. These two factors limit the efficacy and long-term treatment that is necessary for the treatment of many of such diseases. 'Antibody-drug conjugates offer a promising solution by enabling the targeted delivery of small molecule drugs, including immunosuppressives, directly to immune cells, thereby improving safety profiles and optimising exposure duration,' said Dr Boyd-Kirkup. The company, which has leveraged artificial intelligence (AI) in its discovery and development cycle for cancer drugs, will also be doing the same for immunology and inflammatory drugs. Immunology and inflammatory diseases are complex and involve many different cell types. In many cases, the places where the damage is occurring are not linked to the cells or processes happening in the area, said Dr Boyd-Kirkup. AI is being used to understand the biological processes involved in such diseases, he added. 'We have used AI to accelerate identification of key target cells and antigens involved in immunology and inflammatory diseases. The immunology and inflammatory antibody-drug conjugates we are working on are targeting key immune cell types involved in disease,' said Dr Boyd-Kirkup. He added that based on the clinical indications and antibody-drug conjugates that the company is looking into, there is a significant unmet clinical need. 'Clinical trials and commercialisation for therapies generally take around a decade. We are also open to the possibility of accelerating the process to the clinic through partnerships and licensing, which may bring in revenue for the company,' said Dr Boyd-Kirkup. In 2026, the company is also set to release results from its Phase 1B clinical trials for one of its key cancer drugs in development, HMBD-001. It is an antibody that targets the HER3 protein driving tumour growth and resistance against cancer drugs, currently being studied in a number of countries, including Singapore. Correction note: In an earlier version of the story, we referred to the company's chief scientific officer and co-founder as Mr Boyd-Kirkup. This is incorrect. His correct form of address is Dr Boyd-Kirkup.
CNA
3 hours ago
- CNA
CNA938 Rewind - A Letter to Myself: Michael Cheah doesn't just repair cuckoo clocks — he restores memories
Michael Cheah is clearly passionate about his craft — of which he is the only person in Singapore authorised by the Black Forest Clock Association to perform. Michael shares how he ventured into the esoteric world cuckoo clocks on a whim, the trickiest clock he's ever had to fix, and how this journey has given him a sense of joy and purpose.
CNA
4 hours ago
- CNA
Asia First - Wed 13 Aug 2025
02:27:30 Min From the opening bell across markets in Southeast Asia and China, to the biggest business interviews and top financial stories, tune in to Asia First to kick-start your business day.
